PMID- 35359357
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220402
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Solitary Celiac Lymph Node Metastasis Has a Better Long-Term Survival Compared 
      With Solitary Mediastinal Lymph Node Metastasis in Esophagectomy of Esophageal 
      Squamous Cell Cancer: A Propensity Score Matching Analysis.
PG  - 834552
LID - 10.3389/fonc.2022.834552 [doi]
LID - 834552
AB  - BACKGROUND: The prognostic benefit of extensive lymphadenectomy remains 
      controversial in esophageal squamous cell carcinoma (ESCC). The purpose of this 
      retrospective study was to investigate the potential effect of solitary 
      mediastinal (SM) lymph node metastasis and solitary celiac (SC) lymph node 
      metastasis on the short- and long-term outcomes for patients who underwent 
      minimally invasive McKeown esophagectomy. METHODS: From September 2009 to 
      December 2020, a total of 934 cases were diagnosed with ESCC and underwent 
      minimally invasive McKeown esophagectomy in our department; 223 cases met the 
      inclusion and exclusion criteria. Propensity score matching (PSM) was utilized to 
      contrast the postoperative results and long-term survival of Group 1 (SM) and 
      Group 2 (SC). Univariate and multivariate Cox proportional hazards regression 
      analyses were used on possible predictors of survival. RESULTS: One hundred 
      forty-seven patients were available for outcome comparison after PSM. The 
      postoperative results were not significantly different between the two groups. In 
      terms of long-term survival, the 5-year disease-free survival (DFS) was 37.6% and 
      57.3% (p = 0.191) and 5-year disease-specific survival (DSS) was 39.7% and 68.4% 
      (p = 0.028) for Group 1 (SM) and Group 2 (SC), respectively. Univariate and 
      multivariate Cox proportional hazards regression analyses showed that body mass 
      index (BMI), pathologic stage (pStage), and SC/SM grouping had significant hazard 
      ratios (HRs), which suggested that SC is associated with better DSS. CONCLUSION: 
      This cohort study showed that SC lymph node metastasis has a better long-term 
      survival compared with SM lymph node metastasis in esophagectomy of ESCC. The 
      results challenge the current understanding and need confirmation in further 
      research.
CI  - Copyright (c) 2022 Li, Bao, Wang, Zhao, Long, Xie and Guo.
FAU - Li, Kun-Kun
AU  - Li KK
AD  - Department of Thoracic Surgery, Daping Hospital, Army Medical University, 
      Chongqing, China.
FAU - Bao, Tao
AU  - Bao T
AD  - Department of Thoracic Surgery, Daping Hospital, Army Medical University, 
      Chongqing, China.
FAU - Wang, Ying-Jian
AU  - Wang YJ
AD  - Department of Thoracic Surgery, Daping Hospital, Army Medical University, 
      Chongqing, China.
FAU - Zhao, Xiao-Long
AU  - Zhao XL
AD  - Department of Thoracic Surgery, Daping Hospital, Army Medical University, 
      Chongqing, China.
FAU - Long, Jiang
AU  - Long J
AD  - Department of Thoracic Surgery, Daping Hospital, Army Medical University, 
      Chongqing, China.
FAU - Xie, Xian-Feng
AU  - Xie XF
AD  - Department of Thoracic Surgery, Daping Hospital, Army Medical University, 
      Chongqing, China.
FAU - Guo, Wei
AU  - Guo W
AD  - Department of Thoracic Surgery, Daping Hospital, Army Medical University, 
      Chongqing, China.
LA  - eng
PT  - Journal Article
DEP - 20220311
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8963343
OTO - NOTNLM
OT  - esophageal squamous cell carcinoma
OT  - long-term survival
OT  - lymph node metastasis
OT  - minimally invasive esophagectomy
OT  - propensity score matching
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/02 06:00
MHDA- 2022/04/02 06:01
PMCR- 2022/01/01
CRDT- 2022/04/01 05:09
PHST- 2021/12/13 00:00 [received]
PHST- 2022/02/14 00:00 [accepted]
PHST- 2022/04/01 05:09 [entrez]
PHST- 2022/04/02 06:00 [pubmed]
PHST- 2022/04/02 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.834552 [doi]
PST - epublish
SO  - Front Oncol. 2022 Mar 11;12:834552. doi: 10.3389/fonc.2022.834552. eCollection 
      2022.